FDA Greenlights Enhanced Pylarify Formulation, Boosting Prostate Cancer Imaging Access
The FDA has approved Pylarify TruVu, a new formulation of piflufolastat F 18 injection, designed to improve access to PSMA PET imaging for men with prostate cancer. This approval builds upon the initial FDA clearance of Pylarify in May 2021, offering a potentially more stable and readily available diagnostic tool.
Expanding Access to Crucial Diagnostics
Pylarify TruVu is indicated for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer, specifically those with suspected metastasis who are candidates for initial definitive therapy or those experiencing recurrence indicated by elevated prostate-specific antigen (PSA) levels. The new formulation addresses a key need identified by clinicians – greater access to this significant diagnostic technology.
How Pylarify TruVu Differs
The approval of Pylarify TruVu utilized the 505(b)(2) regulatory pathway, leveraging data from two pivotal studies. According to Lantheus Holdings, the manufacturer, Pylarify TruVu is engineered to enhance product stability at higher radioactive concentrations. This improvement is expected to increase batch sizes and enable manufacturing sites equipped with high-energy cyclotrons to produce the agent, ultimately reaching more patients.
The Rise of PSMA PET Imaging
PSMA-targeted PET imaging has develop into increasingly important in prostate cancer management. The FDA initially approved Ga 68 PSMA-11 in December 2020 for similar indications. Though, Pylarify and now Pylarify TruVu, are anticipated to be more widely distributed across the United States due to a broader manufacturing and distribution network.
Looking Ahead: Future Trends in Prostate Cancer Imaging
The approval of Pylarify TruVu signals a continued focus on improving diagnostic accuracy and accessibility in prostate cancer care. Several trends are likely to shape the future of this field:
- Increased Adoption of PSMA PET: As more centers gain access to PSMA PET imaging agents like Pylarify TruVu, its apply will likely become more widespread, influencing treatment decisions for a larger patient population.
- Advancements in Radiopharmaceutical Development: Research is ongoing to develop new radiopharmaceuticals that target different aspects of prostate cancer biology, potentially leading to even more sensitive and specific imaging agents.
- Integration with Artificial Intelligence: AI algorithms are being developed to analyze PSMA PET images, assisting radiologists in identifying subtle lesions and predicting treatment response.
- Personalized Medicine Approaches: Combining PSMA PET imaging with other biomarkers and clinical data will enable more personalized treatment strategies tailored to individual patient characteristics.
“The FDA approval of Pylarify TruVu demonstrates Lantheus’ continued commitment to advancing innovation that directly expands patient access to high-quality diagnostic tools,” said Mary Anne Heino, executive chairperson and CEO of Lantheus Holdings.
Pylarify TruVu is expected to be commercially available in the fourth quarter of 2026.
Frequently Asked Questions
- What is Pylarify TruVu? Pylarify TruVu is a new formulation of piflufolastat F 18 injection used for PET imaging to detect prostate cancer.
- What does PSMA PET imaging do? PSMA PET imaging helps identify prostate cancer lesions, including those that have spread (metastasized) or returned after treatment.
- When will Pylarify TruVu be available? Pylarify TruVu is expected to be commercially available in the fourth quarter of 2026.
Source: Press Release
